Arcus Biosciences
RCUS
128 hedge funds and large institutions have $761M invested in Arcus Biosciences in 2020 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 56 increasing their positions, 37 reducing their positions, and 31 closing their positions.
542% more call options, than puts
Call options by funds: $7.18M | Put options by funds: $1.12M
51% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 37
39% more capital inflows, than outflows
Capital inflows: $177M | Capital outflows: $127M
4.95% less ownership
Funds ownership: 73.34% → 68.39% (-5%)
8% less funds holding
Funds holding: 139 → 128 (-11)
32% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 31
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$20.8M |
| 2 |
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$20.6M |
| 3 |
PFM Health Sciences
San Francisco,
California
|
+$17.9M |
| 4 |
BVF Inc
San Francisco,
California
|
+$16M |
| 5 |
BlackRock
New York
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Peter Svennilson
|
-$43.7M |
| 2 |
Avidity Partners Management
Dallas,
Texas
|
-$14.6M |
| 3 |
Farallon Capital Management
San Francisco,
California
|
-$10.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.92M |
| 5 |
Holocene Advisors
New York
|
-$6.86M |
RCUS Hedge Fund Activity: Q3 2020 in Review
128 of the 4,972 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2020, worth a combined $761M — down 26% from $1.03B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of RCUS and 21 opened new positions — a net loss of 10 holders — while 37 trimmed existing stakes and 56 added.
The largest buyer was State Street, adding an estimated $20.8M. The largest seller was Peter Svennilson, exiting entirely with an estimated $43.7M sold.
- 128 institutional investors held Arcus Biosciences (RCUS) as of Q3 2020, down from 139 in Q2 2020.
- Funds reported $761M of Arcus Biosciences stock for Q3 2020, down 26% quarter-over-quarter.
- 21 funds opened new Arcus Biosciences positions in Q3 2020 and 31 closed out, a net change of -10 holders.
- The largest Arcus Biosciences buyer in Q3 2020 was State Street, an estimated $20.8M added.
- The largest Arcus Biosciences seller in Q3 2020 was Peter Svennilson, an estimated $43.7M sold.
Based on aggregated 13F filings for Q3 2020.